Insulin resistance and impaired functional vasodilation in obese Zucker rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 4, 2008, Pages

  Xiang, Lusha ^a   Dearman, Jennifer ^a   Abram, Sean R ^a   Carter, Cory ^a   Hester, Robert L ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; Diabetes; Prostacyclin; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ARACHIDONIC ACID; GLUCOSE; INSULIN; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SUPEROXIDE; TEMPOL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; INSULIN RESISTANCE; MALE; MUSCLE BLOOD FLOW; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; TRAPEZIUS MUSCLE; VASOCONSTRICTION; VASODILATATION; ZUCKER RAT;

ANIMALS; ANTIOXIDANTS; ARACHIDONIC ACID; ARTERIOLES; BLOOD GLUCOSE; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; HYDRAZINES; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY CORTEX; MALE; MUSCLE, SKELETAL; NADPH OXIDASE; OBESITY; OXIDATIVE STRESS; RATS; RATS, ZUCKER; RECEPTORS, THROMBOXANE; SPIN LABELS; SUPEROXIDES; THIAZOLIDINEDIONES; THROMBOXANES; TIME FACTORS; TRIGLYCERIDES; VASOCONSTRICTION; VASODILATION;

EID: 41749118516     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01206.2007     Document Type: Article

References (61)

1. Ardigo D, Franzini L, Valtuena S, Monti LD, Reaven GM, Zavaroni I. Relation of plasma insulin levels to forearm flow-mediated dilatation in healthy volunteers. Am J Cardiol 97: 1250-1254, 2006.
2. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 286: H742-H748, 2004.
3. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 16: 92-102, 2002.
4. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 103: 1618-1623, 2001.
5. Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M, Wilding JP. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 21: 415-422, 2004.
6. Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol 71: 388-400, 2002.
7. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol 25: 175-184, 1998.
8. Coort SL, Coumans WA, Bonen A, van der Vusse GJ, Glatz JF, Luiken JJ. Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. J Lipid Res 46: 1295-1302, 2005.
9. Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32, Suppl 3: S54-S61, 1998.
10. Cosentino F, Eto M, De Paolis P, van der LB, Bachschmid M, Ullrich V, Kouroedov A, Delli GC, Joch H, Volpe M, Luscher TF. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 107: 1017-1023, 2003.
11. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483: 79-93, 2004.
12. Dai FX, Diederich A, Skopec J, Diederich D. Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol 4: 1327-1336, 1993.
13. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288: 2008-2014, 2002.
14. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 116: 1071-1080, 2006.
15. Evans HL. Rats' activity: influence of light-dark cycle, food presentation and deprivation. Physiol Behav 7: 455-459, 1971.
16. Fortepiani LA, Reckelhoff JF. Increasing oxidative stress with molsidomine increases blood pressure in genetically hypertensive rats but not normotensive controls. Am J Physiol Regul Integr Comp Physiol 289: R763-R770, 2005.
17. Fossum E, Hoieggen A, Moan A, Rostrup M, Nordby G, Kjeldsen SE. Relationship between insulin sensitivity and maximal forearm blood flow in young men. Hypertension 32: 838-843, 1998.
18. Frisbee JC. Vascular adrenergic tone and structural narrowing constrain reactive hyperemia in skeletal muscle of obese Zucker rats. Am J Physiol Heart Circ Physiol 290: H2066-H2074, 2006.
19. Frisbee JC. Hypertension-independent microvascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Microcirculation 12: 383-392, 2005.
20. Frisbee JC. Enhanced arteriolar alpha-adrenergic constriction impairs dilator responses and skeletal muscle perfusion in obese Zucker rats. J Appl Physiol 97: 764-772, 2004.
21. Frisbee JC. Impaired skeletal muscle perfusion in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 285: R1124-R1134, 2003.
22. Frisbee JC. Impaired dilation of skeletal muscle microvessels to reduced oxygen tension in diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 281: H1568-H1574, 2001.
23. Frisbee JC. Impaired dilation of skeletal muscle microvessels to reduced oxygen tension in diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 281: H1568-H1574, 2001.
24. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996.
25. Hester RL, Choi J. Blood flow control during exercise: role for the venular endothelium? Exerc Sport Sci Rev 30: 147-151, 2002.
26. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25: 1804-1809, 2005.
27. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 46: 288-290, 2003.
28. Ishizuka T, Matsui T, Kurita A. Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur J Pharmacol 468: 27-35, 2003.
29. Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol 289: F442-F450, 2005.
30. Kim SH, Park KW, Kim YS, Oh S, Chae IH, Kim HS, Kim CH. Effects of acute hyperglycemia on endothelium-dependent vasodilation in patients with diabetes mellitus or impaired glucose metabolism. Endothelium 10: 65-70, 2003.
31. Komers R, Zdychova J, Cahova M, Kazdova L, Lindsley JN, Anderson S. Renal cyclooxygenase-2 in obese Zucker (fatty) rats. Kidney Int 67: 2151-2158, 2005.
32. Kraml P, Syrovatka P, Stipek S, Fialova L, Koprivova H, Potockova J, Andel M. Hyperlipoproteinemia impairs endothelium-dependent vasodilation. Physiol Res 53: 471-480, 2004.
33. Kuklinska AM, Musial WJ, Kaminski KA, Kralisz P, Modrzejewski W, Sobkowicz B, Dobrzycki S, Stec S, Wojtkowska I. Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronarysyndromes. Rocz Akad Med Bialymst 50: 339 -342, 2005.
34. 2 in contracting rat spinotrapezius muscle. Am J Physiol Heart Circ Physiol 252: H1192-H1202, 1987.
35. Minoura H, Takeshita S, Yamamoto T, Mabuchi M, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Ita M, Mutoh S. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol 519: 182-190, 2005.
36. Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism 52: 1078-1083, 2003.
37. Naik JS, Xiang L, Hester RL. Enhanced role for RhoA-associated kinase in adrenergic-mediated vasoconstriction in gracilis arteries from obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 290: R154-R161, 2006.
38. 2 attenuates functional hyperemia in the hamster cremaster muscle. Am J Physiol Heart Circ Physiol 276: H1289-H1294, 1999.
39. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (post-prandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100: 899-904, 2007.
40. Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 291: H1780-H1787, 2006.
41. Overton JM, Williams TD, Chambers JB, Rashotte ME. Cardiovascular and metabolic responses to fasting and thermoneutrality are conserved in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 280: R1007-R1015, 2001.
42. Pamidimukkala J, Jandhyala BS. Effects of salt rich diet in the obese Zucker rats: studies on renal function during isotonic volume expansion. Clin Exp Hypertens 26: 55-67, 2004.
43. Quilley J, McGiff JC. Renal vascular responsiveness to arachidonic acid in experimental diabetes. Br J Pharmacol 100: 336-340, 1990.
44. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43: 278 -284, 2000.
45. Ruggeri P, Brunori A, Cogo CE, Storace D, Di Nardo F, Burattini R. Enhanced sympathetic reactivity associates with insulin resistance in the young Zucker rat. Am J Physiol Regul Integr Comp Physiol 291: R376-R382, 2006.
46. Shinozaki K, Kashiwagi A, Masada M, Okamura T. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 4: 1-11, 2004.
47. Ter Maaten JC, Bakker SJ, Serne EH, Moshage HJ, Donker AJ, Gans RO. Insulin-mediated increases in renal plasma flow are impaired in insulin-resistant normal subjects. Eur J Clin Invest 30: 1090-1098, 2000.
48. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22: 920-924, 1999.
49. 2 mediation. Am J Physiol Heart Circ Physiol 293: H3096-H3104, 2007.
50. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 20: 2239-2245, 2002.
51. s protein coupling by reducing receptor hyperphosphorylation in obese rats. Am J Physiol Renal Physiol 289: F298-F304, 2005.
52. Verma S, Leung YM, Yao L, Battell M, Dumont AS, McNeill JH. Hyperinsulinemia superimposed on insulin resistance does not elevate blood pressure. Am J Hypertens 14: 429-432, 2001.
53. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 258: 250-256, 2005.
54. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47: 810-814, 1998.
55. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD, Clark MG. Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 51: 3492-3498, 2002.
56. Xiang L, Naik JS, Abram SR, Hester RL. Chronic hyperglycemia impairs functional vasodilation via increasing thromboxane receptor-mediated vasoconstriction. Am J Physiol Heart Circ Physiol 292: H231-H236, 2007.
57. Xiang L, Naik JS, Hodnett BL, Hester RL. Altered arachidonic acid metabolism impairs functional vasodilation in metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 290: R134-R138, 2006.
58. Xiang L, Naik J, Hester RL. Exercise-induced increase in skeletal muscle vasodilatory responses in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 288: R987-R991, 2005.
59. - in DOCA-salt rats. Hypertension 43: 329-334, 2004.
60. 2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia. Immunopharmacology 44: 193-198, 1999.
61. 2 receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51: 198-203, 2002.